Drugs that contain Apalutamide
1. Drug name - ERLEADA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9388159 | JANSSEN BIOTECH | Substituted diazaspiroalkanes as androgen receptor modulators |
Mar, 2027
(4 years from now) | |
| US8445507 | JANSSEN BIOTECH | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
Sep, 2030
(7 years from now) | |
| US9481663 | JANSSEN BIOTECH | Crystalline forms of an androgen receptor modulator |
Jun, 2033
(10 years from now) | |
| CN104619692A | JANSSEN BIOTECH | Crystalline Form Of Androgen Receptor Regulator |
Oct, 2019
(2 years ago) | |
| CN105693692A | JANSSEN BIOTECH | Crystalline Form Of Androgen Receptor Modulator |
Sep, 2021
(1 year, 9 days ago) | |
| CN101454002B | JANSSEN BIOTECH | For The Treatment Of Prostate Cancer And The Androgen Receptor-Related Disease Of Androgen Receptor Modulators |
Mar, 2027
(4 years from now) | |
| CN101454002A | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| IN200809025P1 | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Disease |
Mar, 2027
(4 years from now) | |
| IN283620B | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptorassociated Disease |
Mar, 2027
(4 years from now) | |
| EP2656841B1 | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| EP2004181A2 | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| EP2656841A1 | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| EP3100727A1 | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| EP2656842B1 | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| EP2004181B1 | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| EP3412290A1 | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| EP2656842A3 | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| EP2656842A2 | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| EP3100727B1 | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| EP3412290B1 | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| EP2004181A4 | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| EP2368550A1 | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| EP2368550B1 | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| EP2858985A4 | JANSSEN BIOTECH | Crystalline Forms Of An Androgen Receptor Modulator |
Jun, 2033
(10 years from now) | |
| EP3348553B1 | JANSSEN BIOTECH | Crystalline Forms Of An Androgen Receptor Modulator |
Jun, 2033
(10 years from now) | |
| EP2858985B1 | JANSSEN BIOTECH | Crystalline Forms Of An Androgen Receptor Modulator |
Jun, 2033
(10 years from now) | |
| EP3348553A1 | JANSSEN BIOTECH | Crystalline Forms Of An Androgen Receptor Modulator |
Jun, 2033
(10 years from now) | |
| EP2858985A1 | JANSSEN BIOTECH | Crystalline Forms Of An Androgen Receptor Modulator |
Jun, 2033
(10 years from now) | |
| EP3533792B1 | JANSSEN BIOTECH | Crystalline Forms Of An Androgen Receptor Modulator |
Jun, 2033
(10 years from now) | |
| EP3533792A1 | JANSSEN BIOTECH | Crystalline Forms Of An Androgen Receptor Modulator |
Jun, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9987261 | JANSSEN BIOTECH | Substituted diazaspiroalkanes as androgen receptor modulators |
Mar, 2027
(4 years from now) | |
| US8802689 | JANSSEN BIOTECH | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
Mar, 2027
(4 years from now) | |
| US10849888 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Sep, 2033
(10 years from now) | |
| US9884054 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Sep, 2033
(10 years from now) | |
| US10052314 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Sep, 2033
(10 years from now) | |
| US10702508 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
Apr, 2038
(15 years from now) | |
Treatment: Treatment of non-metastatic, castration-resistant prostate cancer (nm-crpc); treatment of metastatic castration-sensitive prostate cancer (mcspc); Treatment in combination with orchiectomy of non-metastatic, castration-resistant prostate cancer (nmcrpc); Treatment of non-metastatic, castration-resistant prostate cancer (nm-crpc); Treatment in combination with a gnrh agonist of non-metastatic, castration-resistant prostate cancer (nm-crpc); treatment in combination with a gnrh agonist of high risk non-metastatic, castration-resistant prostate cancer (nm-crpc); Treatment in combination with androgen deprivation therapy of non-metastatic, castration-resistant prostate cancer (nmcrpc) that improves metastasis free survival
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 60MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.